SCHEMBL1199569

SCHEMBL1199569

Cc1sc(-c2cccc(C(F)(F)F)c2)cc1Cn1cc(C(=O)O)cn1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.46
KMT2A Q03164 3/20 0.46
NPC1 O15118 1/20 0.46
RAB9A P51151 1/20 0.46
EGLN1 Q9GZT9 2/20 0.46
KCNH2 Q12809 1/20 0.45
ALDH1A1 P00352 2/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
KDM4E B2RXH2 1/20 0.42
XDH P47989 1/20 0.40
PIN1 Q13526 1/20 0.40
KIFC1 Q9BW19 2/20 0.40
GRIN1 Q05586 1/20 0.39
GRIN2B Q13224 1/20 0.39
S1PR1 P21453 1/20 0.39
S1PR3 Q99500 1/20 0.39
CTSA P10619 1/20 0.39
MAPT P10636 1/20 0.38
KDR P35968 1/20 0.38
TEK Q02763 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1198435 0.89 MAPT (0.49) MEN1KMT2AKCNH2ALDH1A1KDM4E
SCHEMBL12876572 0.88 L3MBTL1 (0.40) MEN1KMT2ANPC1RAB9AEGLN1
SCHEMBL1198484 0.83 MEN1 (0.45) MEN1KMT2ANPC1RAB9AEGLN1
SCHEMBL1198884 0.82 MEN1 (0.48) MEN1KMT2ANPC1RAB9AEGLN1
SCHEMBL1198840 0.82 ALDH1A1 (0.53) MEN1KMT2ANPC1RAB9AEGLN1
SCHEMBL1199084 0.82 EGLN1 (0.46) MEN1KMT2ANPC1RAB9AEGLN1
SCHEMBL1198441 0.82 MEN1 (0.50) MEN1KMT2ANPC1RAB9AEGLN1
SCHEMBL1197878 0.81 KMT2A (0.45) MEN1KMT2ANPC1RAB9AEGLN1
SCHEMBL1198136 0.80 ALDH1A1 (0.58) MEN1KMT2ANPC1RAB9AEGLN1
SCHEMBL1198845 0.79 MEN1 (0.47) MEN1KMT2ANPC1RAB9AEGLN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8461348-B2 Heterocyclic derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-06-11 US disclosed
US-20110028493-A1 HETEROCYCLIC DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-02-03 US disclosed
EP-2264017-A1 HETEROCYCLIC DERIVATIVE AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2010-12-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110028493-A1 HETEROCYCLIC DERIVATIVE AND USE THEREOF PDE3B, PDE5A, PDE2A MEN1 2661/4885KMT2A 3197/4885NPC1 3877/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.